# CLRB catalysts: Cellectar Biosciences, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/clrb/catalysts

> Cellectar Biosciences, Inc. (CLRB) has 1 upcoming catalyst. The next is the iopofosine PDUFA date, July 21, 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CLRB?

Cellectar Biosciences, Inc. (CLRB) has 1 upcoming catalyst. The next is the iopofosine PDUFA date, July 21, 2029. SEC Form 10-Q: "The 2024 Tranche A warrants have an exercise price of $75.60 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." [Calendar and source filings](https://sec-api.dev/companies/clrb/catalysts)

Source: SEC Form 10-Q, accession 0001104659-26-124765, https://www.sec.gov/Archives/edgar/data/1279704/000110465926124765/clrb-20260930x10q.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/companies/clrb/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Cellectar Biosciences, Inc. |
| Ticker | CLRB (Nasdaq) |
| SEC CIK | 1279704 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/clrb |

## Cash runway

Cash $24.6M as of 2026-09-30; quarterly burn $9.4M; about 7.8 months of runway at that rate (XBRL company facts, accession 0001104659-26-124765).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 8, 2023 | [Cellectar Biosciences, Inc. topline data readout](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed, positive | "The amounts presented are exclusively cash bonuses paid to the NEOs to satisfy the tax withholding obligations associated with fully vested stock awards received by the NEOs on December 8, 2023 following the release of positive top-line data." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1279704/000141057825000329/clrb-20241231x10k.htm)) |
| November 18, 2024 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465924119941/tm2428692d1_ex99-1.htm)) |
| 1H 2025 | [Payload trial start](https://sec-api.dev/pdufa/payload) | CLRB |  | scheduled | "New Drug applications in the first half of 2025 for both CLR-121225 and CLR- 121125, which will allow the initiation of Phase 1 clinical studies in solid tumor cancers." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465924127487/tm2430732d1_ex99-1.htm)) |
| March 13, 2025 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports Financial Results for Year Ended 2024 and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465925023216/tm259072d1_ex99-1.htm)) |
| May 13, 2025 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465925047568/tm2514904d1_ex99-1.htm)) |
| August 14, 2025 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports Second Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465925078102/tm2523504d1_ex99-1.htm)) |
| November 13, 2025 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "-- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the quarter ended September 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465925110848/tm2531151d1_ex99-1.htm)) |
| March 4, 2026 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports Financial Results for Year Ended 2025 and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465926023169/tm267955d1_ex99-1.htm)) |
| May 14, 2026 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports First Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465926060693/tm2614602d1_ex99-1.htm)) |
| June 2026 | [Iopofosine i 131 single dose primary completion](https://sec-api.dev/pdufa/iopofosine-i-131-single-dose) | CLRB | Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia | delayed | "NCT02952508 (Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-22 (ESTIMATED); Lead Sponsor Cellectar Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02952508)) |
| August 13, 2026 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports Second Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465926095460/tm2623056d1_ex99-1.htm)) |
| November 10, 2026 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports Third Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465926124790/tm2629430d1_ex99-1.htm)) |
| July 21, 2029 | [Iopofosine PDUFA date](https://sec-api.dev/pdufa/iopofosine) | CLRB |  | scheduled | "The 2024 Tranche A warrants have an exercise price of $75.60 and expire at the earlier of (i) ten (10) trading days following the date of the Company's public announcement that the FDA has assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131, and (ii) July 21, 2029." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1279704/000110465926124765/clrb-20260930x10q.htm)) |

## Drugs

- [Iopofosine](https://sec-api.dev/pdufa/iopofosine): 
- [Iopofosine i 131 single dose](https://sec-api.dev/pdufa/iopofosine-i-131-single-dose): Waldenstrom Macroglobulinemia
- [Payload](https://sec-api.dev/pdufa/payload): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/clrb/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CLRB catalysts: Cellectar Biosciences, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/clrb/catalysts

```bibtex
@misc{secapidev_companies_clrb_catalysts_20261116,
  title        = {CLRB catalysts: Cellectar Biosciences, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/clrb/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_clrb_catalysts_20261116","title":"CLRB catalysts: Cellectar Biosciences, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/clrb/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
